Mary Wilson
Well-known member
Posted December 27, 2022.
doi: https://doi.org/10.1101/2022.12.26.521940
Magnus A. G. Hoffmann, Zhi Yang, Kathryn E. Huey-Tubman, Alexander A. Cohen, Priyanthi N. P. Gnanapragasam, Leesa M. Nakatomi, Kaya N. Storm, Woohyun J. Moon, Paulo J.C. Lin, Pamela J. Bjorkman
Abstract
Summary
Prime-boost regimens for COVID-19 vaccines elicit poor antibody responses against Omicron-based variants and employ frequent boosters to maintain antibody levels. We present a natural infection-mimicking technology that combines features of mRNA- and protein nanoparticle-based vaccines through encoding self-assembling enveloped virus-like particles (eVLPs). eVLP assembly is achieved by inserting an ESCRT- and ALIX-binding region (EABR) into the SARS-CoV-2 spike cytoplasmic tail, which recruits ESCRT proteins to induce eVLP budding from cells. Purified spike-EABR eVLPs presented densely-arrayed spikes and elicited potent antibody responses in mice. Two immunizations with mRNA-LNP encoding spike-EABR elicited potent CD8+ T-cell responses and superior neutralizing antibody responses against original and variant SARS-CoV-2 compared to conventional spike-encoding mRNA-LNP and purified spike-EABR eVLPs, improving neutralizing titers >10-fold against Omicron-based variants for three months post-boost. Thus, EABR technology enhances potency and breadth of vaccine-induced responses through antigen presentation on cell surfaces and eVLPs, enabling longer-lasting protection against SARS-CoV-2 and other viruses.
https://www.biorxiv.org/content/10.1101/2022.12.26.521940v1.full
doi: https://doi.org/10.1101/2022.12.26.521940
Magnus A. G. Hoffmann, Zhi Yang, Kathryn E. Huey-Tubman, Alexander A. Cohen, Priyanthi N. P. Gnanapragasam, Leesa M. Nakatomi, Kaya N. Storm, Woohyun J. Moon, Paulo J.C. Lin, Pamela J. Bjorkman
Abstract
Summary
Prime-boost regimens for COVID-19 vaccines elicit poor antibody responses against Omicron-based variants and employ frequent boosters to maintain antibody levels. We present a natural infection-mimicking technology that combines features of mRNA- and protein nanoparticle-based vaccines through encoding self-assembling enveloped virus-like particles (eVLPs). eVLP assembly is achieved by inserting an ESCRT- and ALIX-binding region (EABR) into the SARS-CoV-2 spike cytoplasmic tail, which recruits ESCRT proteins to induce eVLP budding from cells. Purified spike-EABR eVLPs presented densely-arrayed spikes and elicited potent antibody responses in mice. Two immunizations with mRNA-LNP encoding spike-EABR elicited potent CD8+ T-cell responses and superior neutralizing antibody responses against original and variant SARS-CoV-2 compared to conventional spike-encoding mRNA-LNP and purified spike-EABR eVLPs, improving neutralizing titers >10-fold against Omicron-based variants for three months post-boost. Thus, EABR technology enhances potency and breadth of vaccine-induced responses through antigen presentation on cell surfaces and eVLPs, enabling longer-lasting protection against SARS-CoV-2 and other viruses.
https://www.biorxiv.org/content/10.1101/2022.12.26.521940v1.full